Best Life Sciences Companies in Oakland, United States
The 33 best Life Sciences companies in Oakland, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Eko.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Oakland
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Eko Provider of AI-based remote patient monitoring platform for cardiac health 72Funding top 16%Customers top 22%Tech top 25%Product top 30% All 11 signals ▾Fundingtop 16% Customerstop 22% Techtop 25% Producttop 30% Moattop 31% Talenttop 43% AItop 45% Markettop 48% Globalbottom 45% Growthbottom 44% Newsbottom 20% Funding: Raised $167M across 16 rounds · 16 rounds over 11 yrs (1.5/yr) Customers: Play-Store rating 4.81★ across 4,901 ratings (2 apps) · Review volume +17% in 6 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $167M | 18 mo ago | Series D | 95 95 → 204 (+115%) | Jason Bellet Co-Founder | Cart FunctionalityShopifyApple iCloud Mail+40 | — | — |
| 2 | Tempero Bio Developer of therapeutics to treat opioid use disorders | $77M | 24 mo ago | Series B | 2 | — | WixSentryBootstrap+12 | — | — |
| 3 | Versanis Bio Developer of therapeutics for the treatment of obesity | $70M | 62 mo ago | Acquired | 21 | — | — | — | — |
| 4 | Koya Medical Provider of smart wearable compression technology for lymphedema and venous diseases | $37M | 35 mo ago | Series B | 37 | — | WebflowApple iCloud MailMicrosoft Clarity+13 | — | — |
| 5 | Fabric Genomics AI-based disease diagnosis and genomic analysis tool for providers | $33M | 124 mo ago | Acquired | 38 | Paul Billings Co-Founder | WordPressApple iCloud MailGoogle Workspace+27 | 16 patents Bioinformatics software for genomic variant annotation, analysis, and selection. | — |
| 6 | Modis Therapeutics Provider of therapies for rare genetic diseases | $30M | 97 mo ago | Acquired | — | Daniel Pietro Co-Founder | — | — | — |
| 7 | Riffyn Cloud-based software to support the design and learning cycle of research & development | $20M | 89 mo ago | Deadpooled | 35 | — | — | 27 patents Scientific workflow automation and data-driven process design software for R&D labs | — |
| 8 | Manifold AI Provider of an AI platform for life sciences research and development | $18M | 10 mo ago | Series B | 79 | Sourav Dey Cpo & Co-Founder | WebflowApple iCloud MailGoogle Workspace+21 | 8 patents Patents concentrated in mechanical & energy engineering | — |
| 9 | Saccharo Developer of immunotherapies for the treatment of cancer | $7M | 37 mo ago | Series A | 6 | Gregory Moe Co-Founder | — | 11 patents Targeted therapeutic/diagnostic agents binding de‑N‑acetylated polysialic acid (dPSA) | — |
| 10 | November Research Pharmacovigilance software and services | $3M | 149 mo ago | Funding Raised | 5 | — | — | — | — |
| 11 | Rev Genomics Developer of plant breeding technology and licensing of plant cultivars | $2M | 90 mo ago | Seed | 5 | R J Cody Markelz Co-Founder & VP | — | — | — |
| 12 | Concha Labs Provider of hearing aids | $450K | 85 mo ago | Seed | 25 | Amy Li Founder & CEO | Cart FunctionalityShopifyVimeo+16 | 20 patents Personalized hearing aid evaluation, fitting, and AI-driven configuration technologies | — |
| 13 | Nextbiotics Developer of synthetic biology platform to develop genetically engineered viruses | $300K | 93 mo ago | Deadpooled | 3 | Maricel Saenz Co-Founder | — | 3 patents Engineered bacteriophage therapeutics and CRISPR-based antibacterial agents for targeted microbes | — |
Top 12 Life Sciences companies in Oakland
#1
Series D · Oakland, California · founded 2012 · 95 employees$167Mraised▾
Eko offers an AI-based platform for remote monitoring of cardiac health. The solution offered by the company collects real-time patient data and analyses it to generate a report for doctors. The report generated aids in providing proper treatment to patients. The company has also developed products like Duo and Core stethoscopes for heart disease monitoring.
- Apr 2025Grant (prize money)$238.5K
- Jun 2024Series D$41M
- Sep 2022Grant (prize money)$2.3M
- Sep 2022Grant (prize money)$2.7M
#2
Series B · Oakland, California · founded 2016 · 79 employees$18.3Mraised▾
Provider of an AI platform for life sciences research and development. The platform facilitates data analysis, collaboration, and governance for scientific teams. It offers tools for data engineering, cataloging, and visualization, along with pre-configured workspaces. The platform also provides access controls and infrastructure options to maintain data security and compliance. It supports various applications, including trusted research environments and data commercialization.
- Dec 2025Series B$18M
- Nov 2023Series A$15M
- Aug 2020Seed$1.8M
- Dec 2018Seed$1.5M
#3
Series B · Oakland, California · founded 2020 · 2 employees$77Mraised▾
Developer of therapeutics to treat opioid use disorders. The company develops treatments for substance use disorders and related conditions. The company's lead therapeutic drug candidate, TMP-301, is a potent, orally-available, metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) that is being investigated for the treatment of Substance Use Disorders, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD).
- Oct 2024Series B$77M
#4
Series B · Oakland, California · founded 2018 · 37 employees$37Mraised▾
Provider of smart wearable compression technology for lymphedema and venous diseases. The company offers its flagship product Dayspring system which is an FDA-cleared wearable device which offers an active compression system and pump. The device is integrated with an app that indicated the treatment of lymphedema, venous insufficiency, and wound healing time. The device uses patented Flexframe technology.
- Nov 2023Series B—
- Feb 2022Series B$26M
- Dec 2020Series A$11M
- Aug 2020Grant (prize money)$225K
#5
Acquired · Oakland, California · founded 2020 · 21 employees$70Mraised▾
Developer of therapeutics for the treatment of obesity. The company's drug candidate bimagrumab is an activin receptor type II antagonist that builds muscle while reducing fat. The drug is used for the treatment of metabolic disease and obesity.
#6
Series A · Oakland, California · founded 2017 · 6 employees$7.4Mraised▾
Developer of immunotherapies for the treatment of cancer. The company's candidates include monoclonal antibodies which target polysaccharide specific to cancer cells. The target is involved in an immune shielding pathway and serves as a platform for multiple drug modalities.
- Sep 2023Series A$7.4M
#7
Acquired · Oakland, California · founded 2009 · 38 employees$32.8Mraised▾
AI-based disease diagnosis and genomic analysis tool for providers. The flagship product Fabric Enterprise is a combination of primary, secondary and tertiary analytic software for genomics, combined with clinical management tools. The product is used for the detection of hereditary diseases, oncology, and rare disease.
- Jun 2016Series B$23M
- May 2014Grant (prize money)$1.8M
- Jan 2014Series A$8.3M
- Jun 2012Grant (prize money)$1.8M
#8
Acquired · Oakland, California · founded 2016$30Mraised▾
Provider of therapies for rare genetic diseases. The company focuses on Thymidine kinase 2 deficiency which is a genetic disorder that results in mitochondrial dysfunction, leading to inadequate energy production in cells. The company is working on deoxynucleoside combination therapy to restore cellular function in a subset of mitochondrial diseases, mitochondrial DNA (mtDNA) depletion disorders.
- Oct 2018Series A$30M
#9
Deadpooled · Oakland, California · founded 2014 · 35 employees$20Mraised▾
Cloud-based software to support the design and learning cycle of research & development. It has a CAD-like user interface for computer-aided design, and visual process design and can be used to create or modify process flow diagrams that describe all experimental transformations, material sample flows, measured properties, calculations, and specifications. It retains every version of process and experiment designs and uses standard ontologies, such as those provided through the NCBO Bio Portal.
- May 2019Series B$15M
- Aug 2016Series A$3.2M
- Nov 2014Seed$1.8M
#10
Funding Raised · Oakland, California · founded 2003 · 5 employees$3Mraised▾
November Research provides software applications and tools for medical product vigilance. Products include Primo-Mobile and Primo-Desktop application for employees for adverse event (AE) data collection and communication between field representative and PV team and Eureka which is case search and data visualization tool. November Research group's service division has been acquired by High Point.
- May 2014Conventional Debt$1.5M
- Feb 2014Conventional Debt$1.5M
#11
Seed · Oakland, California · founded 2016 · 5 employees$1.6Mraised▾
Developer of plant breeding technology and licensing of plant cultivars. The company offers genomic technology to breeders, cultivators, and seed banks. It provides molecular fingerprints for unique strains and seeds. Advanced tissue culture processes are used for replication of cultivars. The company's technology shortens pheno-hunting timelines. It also offers genomics and bioinformatics analysis.
- May 2019Seed$1.5M
- 2017Seed$120K
#12
Seed · Oakland, California · founded 2017 · 25 employees$450Kraised▾
Concha Labs provides a wearable hearing assistive device, Beta. It has“beeps” which can also help in the hearing test. It can be integrated with any smartphone.
- Sep 2019Grant (prize money)$225K
- Jul 2019Seed—
- Jul 2019Grant (prize money)$225K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.